In this study, we demonstrated that combined targeting of the PI3K/AKT signaling pathway with conventional chemotherapeutics can effectively enhance cytotoxicity in non-small cell lung cancer (NSCLC) models while sparing normal lung fibroblasts. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.